[1]唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,(10):1359-1363,1368.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
　TANG Yinghui,YE Miaoqing,HE Jinyu,et al.Huazhi Fugan granule alleviates Kupffer cell inflammation by inhibiting TLR4/NF-κB/NLRP3 and improves nonalcoholic fatty liver disease[J].,2022,(10):1359-1363,1368.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
点击复制

化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年10期
页码:
1359-1363,1368
栏目:
基础研究
出版日期:
2022-10-05

文章信息/Info

Title:
Huazhi Fugan granule alleviates Kupffer cell inflammation by inhibiting TLR4/NF-κB/NLRP3 and improves nonalcoholic fatty liver disease
作者:
唐颖慧; 叶苗青; 何瑾瑜; 刘皎皎; 李粉萍; 薛敬东; 杨跃青
(陕西省中医医院,陕西 西安 710003)
Author(s):
TANG Yinghui; YE Miaoqing; HE Jinyu; LIU Jiaojiao; LI Fenping; XUE Jingdong; YANG Yueqing
(Shaanxi Provincial Hospital of Traditional Chinese Medicine,Xi'an 710003,China)
关键词:
非酒精性脂肪性肝病;  化脂复肝颗粒;  Kupffer细胞;  TLR4/NF-κB/NLRP3通路;  抑制;  炎症反应;  细胞焦亡;  内毒素血症
Keywords:
Non-alcoholic fatty liver disease;  Huazhi Fugan granules;  Kupffer cells;  TLR4/NF-κB/NLRP3 pathway;  Inhibiting;  Inflammatory response;  Cell pyroptosis;  Endotoxemia
分类号:
R 575.5
DOI:
DOI:10.3969/j.issn.1000-7369.2022.10.008
文献标志码:
A
摘要:
目的:探讨化脂复肝颗粒在非酒精性脂肪性肝病(NAFLD)中对Kupffer细胞(KCs)TLR4/MyD88/NF-κB/NLRP3信号通路的影响。方法:将分离培养的KCs随机分为空白组、LPS干预组、LPS+空白血清组、LPS+化脂复肝组、高糖+对照组、高糖+LPS干预组、高糖+LPS+空白血清组、高糖+LPS+化脂复肝组,LPS干预浓度为100 ng/ml,高糖干预为于KCs培养基中另加入葡萄糖30 mmol/L。用CCK-8法检测各组KCs增殖情况; 酶联免疫吸附法(ELISA)测定各组KCs培养基上清液中促炎因子TNF-α、IL-1β的含量; 反转录实时荧光定量PCR(RT-qPCR)法检测各组KCs中TLR4、MyD88、NLRP3、Caspase-1、NF-κB p65、TNF-α、IL-1β的基因表达情况。结果:CCK-8检测显示,空白及高糖培养对照组KCs细胞不断增殖,长势良好; LPS+化脂复肝组与高糖+LPS+化脂复肝组KCs缓慢增殖,非高糖组KCs均较含高糖组KCs增殖速率更快; 而LPS或高糖+LPS诱导模型组及各加空白血清组KCs于第6小时开始出现凋亡,含高糖组KCs均较非高糖组KCs凋亡速率更快。非高糖各组与含高糖各组中促炎因子TNF-α、IL-1β含量以及炎症相关基因(TLR4、MyD88、NLRP3、Caspase-1、NF-κB/p-65、TNF-α、IL-1β、IL-18)表达水平均呈相同变化趋势,且含高糖各组上述促炎因子及炎症相关基因表达水平均较非高糖组高。以非高糖组为例,LPS诱导模型组和LPS+空白血清组的促炎因子TNF-α与IL-1β含量均显著高于对照组(P<0.05),炎症相关基因TLR4、MyD88等的mRNA表达水平也均显著高于对照组(P<0.05),而LPS诱导模型组与LPS+空白血清组间上述各指标比较差异均无统计学意义(P>0.05); 与LPS诱导模型组或LPS+空白血清组比较,LPS+化脂复肝组促炎因子TNF-α与IL-1β含量均显著降低(P<0.05),炎症相关基因TLR4、MyD88等的mRNA表达水平也均显著降低(P<0.05)。结论:化脂复肝颗粒含药血清可改善KCs活力,有效减轻KCs炎症反应,减少KCs细胞焦亡的发生,具有显著的抗炎、抗氧化损伤及保肝作用,其作用机制可能与抑制TLR4/MyD88/NF-κB p65/NLRP3信号通路的激活相关。
Abstract:
Objective:To investigate the effect of Huazhi Fugan granules on TLR4/MyD88/NF-κB/NLRP3 signaling pathway in KCs in nonalcoholic fatty liver disease(NAFLD).Methods:The isolated and cultured Kupffer cells(KCs)were randomly divided into blank control group,LPS intervention group,LPS+blank serum group,LPS+Huazhi Fugan group,high glucose+control group,high glucose+LPS intervention group,high glucose+LPS+blank serum group,high glucose+LPS+Huazhi Fugan group,LPS intervention concentration was 100 ng/ml,and high glucose intervention was adding glucose 30 mmol/L to KCs medium.The proliferation of KCs in each group was detected by CCK-8 method; the content of pro-inflammatory factors TNF-α and IL-1β in the supernatant of KCs medium in each group was determined by enzyme-linked immunosorbent assay(ELISA); RT-qPCR method to detect the gene expression of TLR4,MyD88,NLRP3,Caspase-1,NF-κB p65,TNF-α,IL-1β in KCs of each group.Results:The detection of CCK-8 showed that KCs cells in the blank and high glucose culture control groups proliferated continuously and grew well; KCs in the LPS+HZFGXQ group and the high glucose+LPS+Huazhi Fugan group proliferated slowly,and the KCs in the non-high glucose group were higher than those in the high glucose group.The proliferation rate of KCs was faster; while the KCs in the LPS or high glucose+LPS-induced model group and the blank serum groups began to appear apoptosis at 6 h,and the apoptosis rate of KCs in the high glucose group was faster than that in the non-high glucose group.The contents of pro-inflammatory factors TNF-α,IL-1β and inflammation-related genes(TLR4,MyD88,NLRP3,Caspase-1,NF-κB p65,TNF-α,IL-1β,IL-18)showed the same trend of change,and the expression levels of the above pro-inflammatory factors and inflammation-related genes in each group containing high glucose were higher than those in the non-high glucose group.Taking the non-high glucose group as an example,the contents of pro-inflammatory factors TNF-α and IL-1β in the LPS-induced model group and the LPS+blank serum group were significantly higher than those in the control group(P<0.05),and the mRNAs of inflammation-related genes TLR4 and MyD88 were significantly higher than those in the control group(P<0.05).The expression levels were also significantly higher than those in the control group(P<0.05),while there was no significant difference in the above indexes between the LPS-induced model group and the LPS+blank serum group(P>0.05); Compared with the LPS-induced model group or the LPS+blank serum group Compared with the LPS+Huazhi Fugan group,the contents of pro-inflammatory factors TNF-α and IL-1β were significantly decreased(P<0.05),and the mRNA expression levels of inflammation-related genes TLR4 and MyD88 were also significantly decreased(P<0.05).Conclusion:Huazhi Fugan granule-containing serum can improve the viability of KCs,effectively reduce the inflammatory response of KCs,and reduce the occurrence of KCs cell pyroptosis.It has significant anti-inflammatory,anti-oxidative damage and hepatoprotective effects.Inhibited activation of TLR4/MyD88/NF-κB p65/NLRP3 signaling pathway.

参考文献/References:

[1] Dai W,Ye L,Liu A,et al.Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus:A meta-analysis[J].Medicine(Baltimore),2017,96(39):e8179.
[2] Wang L,Gao P,Zhang M,et al.Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J].JAMA,2017,317(24):2515-2523.
[3] 肖 洋,柯 婷,李 婷,等.运脾化浊颗粒对糖尿病合并脂肪肝大鼠模型的干预机制[J].陕西中医,2021,42(12):1680-1683.
[4] 陕西省中医医院肝病科.肥胖、脂肪肝与中医无饥饿禁食疗法[J].陕西中医,2019,40(5):681.
[5] 薛敬东,李粉萍,李煜国,等.化脂复肝颗粒治疗脂肪肝作用机理的研究[J].中国中医基础医学杂志,2004,10(4):26-27.
[6] 张 欣,赵玉生,薛敬东,等.化脂复肝颗粒治疗脂肪肝124 例[J].上海中医药杂志,2004,38(6):23-24.
[7] 李小瑞,薛敬东.名中医薛敬东主任医师运用化脂复肝颗粒治疗脂肪肝的临床经验[J].现代养生,2017,17(8):165-166.
[8] Riveraca A,Rooijen N.Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis [J].J Hepatol,2007,47(4):571-579.
[9] Vespasiani-Gentilucci U,Carotti S,Perrone G,et al.Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD [J].Liver Int,2015,35(2):569-581.
[10] Rivera CA,Adegboyega P,Rooijen N,et al.Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis[J].J Hepatol,2007,47(4):571-579.
[11] Dallio M,Romeo M,Gravina AG,et al.Nutrigenomics and nutrigenetics in metabolic-(dysfunction)associated fatty liver disease:Novel insights and future perspectives[J].Nutrients,2021,13(5):1679.
[12] Thanapirom K,Tsochatzis EA.Non-alcoholic fatty liver disease(nafld)and the quest for effective treatments [J].Hepatobiliary Surg Nutr,2019,8(1):77-79.
[13] Adams LA,Anstee QM,Tilg H,et al.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases [J].Gut,2017,66(6):1138-1153.
[14] 巴明玉,娄永强,禄保平.健脾疏肝降脂方干预非酒精性肪肝病肥胖小鼠功能、游离脂肪酸机制探讨[J].陕西中医,2020,42(4):434-436.
[15] 王敏娟,王敏雯,郭 艳,等.膳食炎症指数与老年人非酒精性脂肪性肝病关系研究[J].陕西医学杂志,2020,49(12):1589-1592.
[16] Mota M,Banini BA,Cazanave SC,et al.Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease[J].Metabolism,2016,65(8):1049-1061.
[17] Fang Y,Chen H,Wang C,et al.Pathogenesis of non-alcoholic fatty liver disease in children and adolescence:From “two hit theory” to “multiple hit model” [J].World J Gastroenterol,2018,4(27):2974-2983.
[18] Buzzetti E,Pinzani M,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J].Metabolism,2016,65(8):1038-1048.
[19] Wynn TA,Chawla A,Pollard JW.Macrophage biology in development,homeostasis and disease[J].Nature,2013,496(7446):445-455.
[20] Eckert C,Klein N,Kornek M,et al.The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation [J].Front Immunol,2015,6:179.
[21] Meli R,Mattace RG,Calignano A.Role of innate immune response in non-alcoholic fatty liver disease:Metabolic complications and therapeutic tools [J].Front Immunol,2014,5:177.
[22] Wree A,Mcgeough MD,Pena CA,et al.Nlrp3 inflammasome activation is required for fibrosis development in nafld [J].J Mol Med(Berl),2014,92(10):1069-1082.
[23] Cai D,Yuan M,Frantz DF,et al.Local and systemic Insulin resistance resulting from hepatic activation of Ikk-Beta and Nf-Kappab [J].Nature Medicine,2005,11(2):183-190.
[24] Frasinariu OE,Ceccarelli S,Alisi A,et al.Gut-liver axis and fibrosis in nonalcoholic fatty liver disease:An input for novel therapies [J].Dig Liver Dis,2013,45(7):543-551.

相似文献/References:

[1]黄 进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,(2):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
　HUANG Jin,LU Xueping.Analysis of treatment of nonalcoholic fatty liver disease from spleen[J].,2021,(10):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
[2]林先佳,王小锋,张媛媛,等.基于网络药理学和分子对接探讨肝脂平治疗非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(4):524.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.027]
[3]赵梦溪,罗 斌,吕建瑞,等.隐丹参酮调节AMPK/Nrf2信号通路治疗小鼠非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(8):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
　ZHAO Mengxi,LUO Bin,LYU Jianrui,et al.Mechanism of cryptotanshinone regulates AMPK/Nrf2 signaling pathway to treat nonalcoholic fatty liver disease in mouse[J].,2023,(10):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
[4]杨 帆,李 娟,何 昉,等.利胆退黄汤治疗非酒精性脂肪性肝病疗效及对患者肝功能、糖脂代谢和血清脂肪因子的影响[J].陕西中医,2023,(10):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
　YANG Fan,LI Juan,HE Fang,et al.Lidan Tuihuang decoction on liver function,glycolipid metabolism,and serum adipose factors in the treatment of non alcoholic fatty liver disease[J].,2023,(10):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
[5]李秀秀,张玉佩,许春玲,等.基于胆汁酸-肠道菌群对话机制探讨非酒精性脂肪性肝病肝郁脾虚病机特点[J].陕西中医,2024,(6):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
　LI Xiuxiu,ZHANG Yupei,XU Chunling,et al.Exploration of the pathogenic characteristics of non-alcoholic fatty liver disease with liver depression and spleen deficiency based on the bile acid-gut microbiota dialogue mechanism[J].,2024,(10):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
[6]罗 艺,周晓玲,刘 琳,等.非酒精性脂肪性肝病中医治疗研究进展[J].陕西中医,2024,(6):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]
　LUO Yi,ZHOU Xiaoling,LIU Lin,et al.Research progress on traditional Chinese medicine treatment of nonalcoholic fatty liver disease[J].,2024,(10):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]

备注/Memo

备注/Memo:
基金项目:国家中医药管理局区域中医(肝病)诊疗中心培育单位建设项目[国中医药办医政函(2017)39号]; 陕西省中医药管理局中医药科研项目(2021-ZZ-JC035); 陕西省感染性疾病临床医学研究中心(中西医结合)建设项目(2020LCZX-02); 陕西省中医医院院级课题(2020-02)
更新日期/Last Update: 2022-10-09